Teladoc ( (TDOC) ) has fallen by -7.49%. Read on to learn why.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Teladoc’s stock has seen a notable decline of 7.49% over the past week, reflecting investor concerns amidst a series of Hold ratings from analysts. Analysts from TD Cowen, Truist Financial, and Evercore ISI have all maintained a Hold stance on the stock, with price targets hovering around the $8.00 mark. Despite these cautious ratings, Canaccord Genuity has maintained a Buy rating, suggesting some optimism in the market. The company’s market cap stands at $1.53 billion, with a P/E ratio of -6.74, indicating financial challenges.
The recent earnings call from Teladoc highlighted both achievements and hurdles. The company exceeded its revenue and EBITDA guidance midpoints, driven by strong international growth and expansion in the mental health sector. However, challenges in the U.S. cash pay segment, particularly with BetterHelp, and a goodwill impairment charge have clouded the financial outlook. These factors have contributed to the stock’s downward movement as investors weigh the company’s growth prospects against its current challenges.
Looking forward, Teladoc has updated its full-year guidance, projecting consolidated revenue between $2.510 billion and $2.539 billion, and adjusted EBITDA ranging from $270 million to $287 million. Despite the recent stock price dip, the company remains optimistic about its future, focusing on expanding its services and improving operational efficiency. Investors will be closely watching how Teladoc navigates its strategic and financial challenges in the coming months.